Department of Pathology, Center for Vascular Biology Research, Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215,
J Biol Chem. 2010 Nov 5;285(45):34999-5010. doi: 10.1074/jbc.M110.164418. Epub 2010 Aug 25.
The PDZ1 domain of the four PDZ domain-containing protein PDZK1 has been reported to bind the C terminus of the HDL receptor scavenger receptor class B, type I (SR-BI), and to control hepatic SR-BI expression and function. We generated wild-type (WT) and mutant murine PDZ1 domains, the mutants bearing single amino acid substitutions in their carboxylate binding loop (Lys(14)-Xaa(4)-Asn(19)-Tyr-Gly-Phe-Phe-Leu(24)), and measured their binding affinity for a 7-residue peptide corresponding to the C terminus of SR-BI ((503)VLQEAKL(509)). The Y20A and G21Y substitutions abrogated all binding activity. Surprisingly, binding affinities (K(d)) of the K14A and F22A mutants were 3.2 and 4.0 μM, respectively, similar to 2.6 μM measured for the WT PDZ1. To understand these findings, we determined the high resolution structure of WT PDZ1 bound to a 5-residue sequence from the C-terminal SR-BI ((505)QEAKL(509)) using x-ray crystallography. In addition, we incorporated the K14A and Y20A substitutions into full-length PDZK1 liver-specific transgenes and expressed them in WT and PDZK1 knock-out mice. In WT mice, the transgenes did not alter endogenous hepatic SR-BI protein expression (intracellular distribution or amount) or lipoprotein metabolism (total plasma cholesterol, lipoprotein size distribution). In PDZK1 knock-out mice, as expected, the K14A mutant behaved like wild-type PDZK1 and completely corrected their hepatic SR-BI and plasma lipoprotein abnormalities. Unexpectedly, the 10-20-fold overexpressed Y20A mutant also substantially, but not completely, corrected these abnormalities. The results suggest that there may be an additional site(s) within PDZK1 that bind(s) SR-BI and mediate(s) productive SR-BI-PDZK1 interaction previously attributed exclusively to the canonical binding of the C-terminal SR-BI to PDZ1.
PDZK1 是一种含有四个 PDZ 结构域的蛋白,其 PDZ1 结构域已被报道可以与 HDL 受体清道夫受体 B 型,I 类(SR-BI)的 C 末端结合,并控制肝脏 SR-BI 的表达和功能。我们生成了野生型(WT)和突变型的鼠 PDZ1 结构域,突变体在其羧酸盐结合环(Lys(14)-Xaa(4)-Asn(19)-Tyr-Gly-Phe-Phe-Leu(24))中有单个氨基酸取代,并测量了它们对对应于 SR-BI C 末端的 7 个残基肽((503)VLQEAKL(509))的结合亲和力。Y20A 和 G21Y 取代完全消除了所有结合活性。令人惊讶的是,K14A 和 F22A 突变体的结合亲和力(K(d))分别为 3.2 和 4.0 μM,与 WT PDZ1 测量的 2.6 μM 相似。为了理解这些发现,我们使用 X 射线晶体学确定了 WT PDZ1 与来自 SR-BI C 末端的 5 个残基序列((505)QEAKL(509))结合的高分辨率结构。此外,我们将 K14A 和 Y20A 取代物纳入全长 PDZK1 肝特异性转基因中,并在 WT 和 PDZK1 敲除小鼠中表达它们。在 WT 小鼠中,转基因没有改变内源性肝 SR-BI 蛋白表达(细胞内分布或数量)或脂蛋白代谢(总血浆胆固醇,脂蛋白大小分布)。在 PDZK1 敲除小鼠中,正如预期的那样,K14A 突变体的行为与野生型 PDZK1 相同,并完全纠正了它们的肝 SR-BI 和血浆脂蛋白异常。出乎意料的是,10-20 倍过表达的 Y20A 突变体也部分但不完全纠正了这些异常。结果表明,在 PDZK1 中可能存在一个或多个其他结合位点,可以与 SR-BI 结合,并介导以前归因于 C 末端 SR-BI 与 PDZ1 之间的典型结合的有功能的 SR-BI-PDZK1 相互作用。